133027-56-2

Basic information

• Product Name: Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)-
• CAS NO: 133027-56-2
• Molecular Formula: C17H29BrOSi
• Molecular Weight: 357.406
• Mol File: 133027-56-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)-(133027-56-2)
• EPA Substance Registry System: Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)-(133027-56-2)

Safety Data

• Hazardous Substances Data: 133027-56-2(Hazardous Substances Data)

Usage

General Description

Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)- is a chemical compound with a complex molecular structure. It contains a silane group, which is a type of organic compound that contains a silicon atom bonded to hydrogen atoms. The compound also contains a 3-(2-bromophenyl)propoxy group, which is a combination of a phenyl group (a six-carbon aromatic ring) with a bromine atom and a propoxy group (a three-carbon chain attached to an oxygen atom). In addition, it has two dimethyl groups and a 1,1,2-trimethylpropyl group, adding further complexity to its structure. Silane, [3-(2-bromophenyl)propoxy]dimethyl(1,1,2-trimethylpropyl)- is likely used in various industrial applications, such as in the production of silicones or as a coupling agent in the synthesis of organic compounds.

Upstream product

• 102540-15-8 methyl (2E)-3-(2-bromophenyl)-2-propenoate 
• 66191-86-4 3-(2-bromophenyl)propanoic acid,methyl ester 
• 6630-33-7 ortho-bromobenzaldehyde 
• 52221-92-8 3-(2-bromo-phenyl)-propan-1-ol 
• 67373-56-2 chlorodimethyl(1,1,2-trimethylpropyl)silane 

Downstream Products

• 135613-36-4 anti-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 135682-58-5 syn-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 135613-37-5 <1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenebutanoic acid 
• 135613-50-2 C₂₅H₂₉N₃O₄ 
• 133027-60-8 Acetic acid (1R,2R,3R,4S)-3-(2-{3-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl ester 
• 135613-48-8 4-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-butyric acid methyl ester 
• 135613-47-7 4-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-1-diazo-butan-2-one 
• 135613-45-5 3-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-propionic acid methyl ester 
• 135682-55-2 [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol 
• 135613-46-6 3-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-propionic acid 
• 135613-44-4 <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenebutanoic acid, methyl ester 
• 142757-90-2 [1S-(1α,2α,3α,4α)]-2-[[3-[(Acetyloxy)methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid 
• 135613-49-9 (1R,2S,3R,4S)-3-[2-(3-formyl-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl]propionic acid methyl ester 
• 135682-53-0 <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid, methyl ester 

Relevant articles and documents

Prostaglandin analogs

Thromboxane receptor antagonist activity is exhibited by compounds of the formula STR1 wherein: V is --(CH 2) m --, --O--, or STR2 but if V is --O--or STR3 R 3 and R 4 must complete an aromatic ring; W is --(CH 2) 2 --, --CH CH-- or phenylene;X is a single bond, --CH CH--, --(CH 2) n --, or --O--(CH 2) n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long;Y is --CO 2 H, --CO 2 alkyl, --CO 2 alkali metal, --CH 2 OH, --CONHSO 2 R 5, --CONHR 6, or --CH 2 -5-tetrazolyl;Z is O or NH;R 3 and R 4 are each independently hydrogen or alkyl or R 3 and R 4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.

7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasospastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is O, if Z is STR3 then Y cannot be O, and when Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 -5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.

7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasopastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is 0, if Z is STR3 then Y cannot be O, and Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 --5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.